Biotechnology News and Research

RSS

AI-based technology accelerates discovery of new tuberculosis drug candidates

Tuberculosis is a serious global health threat that infected more than 10 million people in 2022. Spread through the air and into the lungs, the pathogen that causes "TB" can lead to chronic cough, chest pains, fatigue, fever and weight loss.

7 Feb 2025

New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovative technology from WashU in 2022.

5 Feb 2025

New method uses DNA sequencing for precise metabolite measurement

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This enables rapid and precise analysis of biological compounds, such as sugars, vitamins, hormones and the hundreds of other metabolites that are critical for health.

4 Feb 2025

Engineered fat cells starve tumors and prevent cancer growth

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab experiments.

4 Feb 2025

New approach unveiled to accurately predict and engineer protein metalation

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.

29 Jan 2025

Disperazol Pharma joins the AMR Industry Alliance to combat antimicrobial resistance

Disperazol Pharma, a leading biotechnology firm that develops compounds that dismantle biofilms of critical Gram—negative pathogens, today announced that it has joined the AMR Industry Alliance. AMR is currently responsible for an estimated 1.27 million deaths annually worldwide, with projections warning of even greater impacts if action is delayed.

From Disperazol Pharma ApS 29 Jan 2025

Schrödinger selects Sapio Sciences to enhance in silico drug discovery from plasmid to structure

Sapio Sciences, the science-aware™ lab informatics platform, today announced that Schrödinger, a global leader in computational chemistry, has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules.

From Sapio Sciences 29 Jan 2025

Trilobio introduces whole-laboratory automation platform at SLAS2025

Trilobio, developer of whole lab automation solutions for advancing biology research, today introduced the first version of its comprehensive robotics, lab equipment and software platform at the Society for Laboratory Automation and Screening conference, SLAS2025, alongside pilot customer data, demonstrating the platform's abilities in advancing research workflows.

From Trilobio 28 Jan 2025

Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego.

27 Jan 2025

MIT breakthrough enables fast and uniform protein labeling in 3D tissues

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D tissues with unprecedented speed, uniformity, and versatility.

24 Jan 2025

Research could lead to better medicines and new tools in synthetic biology

Proteins are life's engines, powering processes like muscle movement, vision, and chemical reactions. Their environments-water, lipid membranes, or other condensed phases-are critical to their function, shaping their structure and interactions.

24 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

New approach shows promise in fighting multiple cancers

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor's cancerous cells influence their surroundings, blocking the body's immune defenses and creating a sort of haven in which the tumor can grow. Treatments that target some of these pro-tumor actions are effective in a number of cancers, but only for some patients; in others, these treatments have little effect.

17 Jan 2025

Monmouth Scientific Modular Cleanroom expansion enhances production for Womed

Womed's cleanroom expansion, designed by Monmouth Scientific, optimizes production with ISO 7 compliance and enhanced workflow for medical device manufacturing.

From Monmouth Scientific 16 Jan 2025

Pittcon to make historic first appearance in Boston’s world-leading scientific hub

Pittcon 2025 in Boston: a landmark event uniting industry and academia to advance analytical chemistry and foster groundbreaking scientific collaboration.

From Pittcon 16 Jan 2025

Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.

15 Jan 2025

Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer's disease diagnosis

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

From Spear Bio 15 Jan 2025

Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802

From Pheno Therapeutics 15 Jan 2025

UQ and Vaxxas win global prize to accelerate patch-based mRNA vaccine for COVID-19

The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

13 Jan 2025

Enhanced biosensing technology detects molecules at lower concentrations

An unplugged electric instrument may function, but it sounds much better when it is connected to an amplifier.